ORYZON awarded 13.26 million € through the first Important Project of Common European Inte... 08/05/2025 Healthcare Rare diseases Innovative drugs Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases. Partners - Oryzon Genomics
Nuage Therapeutics, Ona Therapeutics, and SpliceBio are leading the wave of biotech innova... 05/05/2025 Healthcare Rare diseases Personalized medicine Advanced therapies Las biotecnológicas Nuage Therapeutics, Ona Therapeutics y SpliceBio, con sede en el Parque Científico de Barcelona, han... Partners - Parc Científic de Barcelona
Biotechnology opens the door to gene therapies for rare diseases 27/02/2025 Healthcare Rare diseases Despite advances in biotechnology and research, the lack of specialists, scarcity of treatments, and inequality in... AseBio
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric pati... 11/12/2024 Healthcare Rare diseases Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural... Partners - Minoryx Therapeutics
Rare Disease Summit Philadelphia USA Del 18/03/2025 to 20/03/2025 Healthcare Rare diseases International
Biotechnology revolutionizes the diagnosis and treatment of lymphoma, the seventh most com... 15/09/2024 Healthcare Rare diseases Personalized medicine Advanced therapies It is estimated that in 2024, around 12,400 new cases of lymphoma will be diagnosed in Spain, the majority... AseBio
Biotechnology revolutionizes the diagnosis and treatment of lymphoma, the seventh most com... 15/09/2024 There are more than 40 types of lymphomas that can generally be grouped into two major subgroups: Hodgkin lymphoma and... AseBio
ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decis... 03/09/2024 Healthcare Rare diseases Innovative drugs In Australia, Malaysia and Mexico. Partners - Oryzon Genomics
How to Leverage Real-World Evidence for Market Access in Rare Disease 16/08/2024 Healthcare Rare diseases A good way to identify the right data source for a targeted rare disease is to perform a real-world data (RWD) source... Partners
Integra Therapeutics to receive up to €10.5 million from European Commission for its FiCAT... 17/07/2024 Healthcare Access to innovation Rare diseases Advanced therapies EU projects This funding will enable Integra Therapeutics to launch its first gene therapy to treat a serious pediatric hepatic... Partners - Integra Therapeutics S.L.
